In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
